Bookmark and Share

(XXII) to Hold Conference Call to Provide Business Update For Investors

22nd Century Group, Inc. (NYSE MKT:XXII) announced today that Henry Sicignano III, President and Chief Operating Officer of 22nd Century Group, together with Richard M. Sanders, an independent Director of 22nd Century Group, will provide a business update for investors on Tuesday, November 25th at 10:00 AM (EST).

The conference call is expected to reach hundreds of participants from the investment sector and tobacco industry. Chardan Capital Markets Senior Research Analyst, James McIlree, will moderate the call. Interested parties are invited to participate in the call by dialing: (888) 438-5525 and using Conference ID 6119197.

The conference call will consist of a brief overview of recent business highlights and a summary of the Company’s plans for the first half of 2015. Immediately thereafter, there will be a question and answer segment open to all callers.

Henry Sicignano stated, “We believe that recent changes by 22nd Century that place primary focus on near-term revenue opportunities will be beneficial to the Company and to shareholder value. Accordingly, we are pleased to be able to provide a business update to increase awareness about our Company and to describe our excellent business prospects.”

For additional information, please visit: www.xxiicentury.com

22nd Century Group to Present at LD Micro Investor Conference on December 3rd

Separately, 22nd Century announced today that the Company will be a featured presenter at the LD Micro Investor Conference in Los Angeles, California. Mr. Sicignano will make a presentation to institutional investors and high net worth retail investors at this invitational conference on Wednesday, December 3rd, 2014 at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles.

“We are honored to have 22nd Century Group present at the conference,” stated Chris Lahiji, President of LD Micro.

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. The Company’s technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant. 22nd Century owns or is the exclusive licensee of 129 issued patents in 78 countries plus an additional 51 pending patent applications; 22nd Century also holds co-exclusive rights to another 16 patent applications. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Botanical Genetics is focused on novel cannabis plant varieties and on cannabis-based products. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

Redington, Inc.
Tom Redington, 203-222-7399

Friday, November 21st, 2014 Uncategorized
Top Small Cap Market News